

Paola Sarchielli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6030414/publications.pdf>

Version: 2024-02-01

111
papers

4,659
citations

94433

37
h-index

110387

64
g-index

117
all docs

117
docs citations

117
times ranked

5525
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological findings in patients with migraine and other primary headaches: a narrative review. <i>Clinical and Experimental Immunology</i> , 2022, 207, 11-26.	2.6	18
2	Pathophysiological Bases of Comorbidity in Migraine. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 640574.	2.0	57
3	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. <i>Journal of Neuroinflammation</i> , 2021, 18, 259.	7.2	20
4	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	6.4	38
5	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577108.	2.3	31
6	Dural arteriovenous fistulas and headache features: an observational study. <i>Journal of Headache and Pain</i> , 2020, 21, 6.	6.0	13
7	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	2.0	20
8	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. <i>Stroke</i> , 2019, 50, 2555-2557.	2.0	20
9	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. <i>Journal of Headache and Pain</i> , 2019, 20, 92.	6.0	116
10	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	3.6	41
11	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		0
12	Teaching Images in Headache: Thrombosis of Posterior Communicating Artery Aneurysm. <i>Headache</i> , 2019, 59, 630-631.	3.9	0
13	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. <i>Journal of Neurology</i> , 2018, 265, 522-529.	3.6	5
14	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	6.2	111
15	Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. <i>Neurodegenerative Disease Management</i> , 2018, 8, 105-113.	2.2	12
16	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. <i>Cephalalgia</i> , 2018, 38, 274-282.	3.9	19
17	Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study. <i>Stroke Research and Treatment</i> , 2018, 2018, 1-9.	0.8	13
18	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	3.6	43

#	ARTICLE	IF	CITATIONS
19	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , 2018, 19, 101.	6.0	34
20	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , 2018, 19, 98.	6.0	18
21	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Journal of Neurology</i> , 2018, 265, 2684-2687.	3.6	35
22	Noninvasive vagus nerve stimulation as acute therapy for migraine. <i>Neurology</i> , 2018, 91, e364-e373.	1.1	186
23	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 217-219.	2.0	5
24	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , 2017, 18, 66.	6.0	27
25	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. <i>Journal of the Neurological Sciences</i> , 2017, 379, 236-240.	0.6	12
26	Epilepsy Comorbidity. <i>Headache</i> , 2017, , 41-63.	0.4	0
27	Genotype-phenotype correlation of F484L mutation in three Italian families with Thomsen myotonia. <i>Muscle and Nerve</i> , 2017, 55, E24-E25.	2.2	1
28	Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine. <i>Frontiers in Neurology</i> , 2017, 8, 655.	2.4	19
29	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. <i>Journal of Neurology</i> , 2016, 263, 1449-1451.	3.6	2
30	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. <i>European Neurology</i> , 2016, 76, 62-68.	1.4	4
31	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	3.3	68
32	Retinopathy during interferon- β treatment for multiple sclerosis: case report and review of the literature. <i>Journal of Neurology</i> , 2016, 263, 422-427.	3.6	12
33	P066. Migraine with aura in the locker room: 4 case reports. <i>Journal of Headache and Pain</i> , 2015, 16, A169.	6.0	0
34	Migraine and epilepsy: what value today?. <i>Journal of Headache and Pain</i> , 2015, 16, A44.	6.0	2
35	Medication-overuse headache: an update. <i>Journal of Headache and Pain</i> , 2015, 16, A46.	6.0	0
36	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. <i>Journal of Headache and Pain</i> , 2015, 16, A69.	6.0	0

#	ARTICLE	IF	CITATIONS
37	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. <i>Human Genomics</i> , 2015, 9, 30.	2.9	7
38	Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2015, 77, 697-709.	5.3	45
39	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. <i>Brain Research</i> , 2015, 1621, 205-213.	2.2	30
40	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. <i>BMC Neurology</i> , 2015, 15, 85.	1.8	10
41	Infliximab monotherapy for neuro-Behçet's disease: A case report. <i>Journal of the Neurological Sciences</i> , 2014, 347, 389-390.	0.6	8
42	Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. <i>Journal of Headache and Pain</i> , 2014, 15, 88.	6.0	5
43	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1289-1297.	0.7	55
44	A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. <i>Cephalalgia</i> , 2014, 34, 68-72.	3.9	28
45	Genes and primary headaches: discovering new potential therapeutic targets. <i>Journal of Headache and Pain</i> , 2013, 14, 61.	6.0	16
46	Cortical spreading depression as a target for anti-migraine agents. <i>Journal of Headache and Pain</i> , 2013, 14, 62.	6.0	110
47	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. <i>Neurobiology of Disease</i> , 2013, 52, 229-236.	4.4	155
48	Expression of cathepsins S and D signals a distinctive biochemical trait in CD34 ⁺ hematopoietic stem cells of relapsing/remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1443-1453.	3.0	12
49	Immunological Profile of Silent Brain Infarction and Lacunar Stroke. <i>PLoS ONE</i> , 2013, 8, e68428.	2.5	20
50	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. <i>Neurology</i> , 2012, 79, 1182-1184.	1.1	27
51	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	7.1	113
52	Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. <i>Journal of Headache and Pain</i> , 2012, 13, 677-684.	6.0	67
53	Drug-dependence behaviour and outcome of medication-overuse headache after treatment. <i>Journal of Headache and Pain</i> , 2012, 13, 653-660.	6.0	33
54	Italian guidelines for primary headaches: 2012 revised version. <i>Journal of Headache and Pain</i> , 2012, 13, 31-70.	6.0	129

#	ARTICLE	IF	CITATIONS
55	Migraine with aura in the locker room: three case reports. <i>Journal of Headache and Pain</i> , 2012, 13, 91-93.	6.0	7
56	Medication Overuse Headache: Causes, Consequences, and Treatment. , 2012, , 351-362.		0
57	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 323-324.	3.6	12
58	Palinopsia in patients with migraine: A case-control study. <i>Cephalalgia</i> , 2011, 31, 999-1004.	3.9	33
59	Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. <i>Cephalalgia</i> , 2011, 31, 543-549.	3.9	16
60	Occipital arteriovenous malformations and migraine. <i>Cephalalgia</i> , 2011, 31, 1320-1324.	3.9	25
61	Medication overuse headache: Neurobiological, behavioural and therapeutic aspects. <i>Pain</i> , 2010, 150, 222-224.	4.2	30
62	Obsessiveâ€Compulsive Disorder and Migraine With Medicationâ€Overuse Headache. <i>Headache</i> , 2009, 49, 1005-1013.	3.9	56
63	Pathophysiological basis of migraine prophylaxis. <i>Progress in Neurobiology</i> , 2009, 89, 176-192.	5.7	100
64	Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1-8.	1.9	77
65	Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. <i>Journal of Headache and Pain</i> , 2008, 9, 367-373.	6.0	35
66	Association Between Migraine and Headache Attributed to Stroke: A Caseâ€Control Study. <i>Headache</i> , 2008, 48, 1468-1475.	3.9	7
67	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. <i>Neuroscience Letters</i> , 2008, 435, 223-228.	2.1	52
68	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 402-412.	8.7	172
69	Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 705-721.	5.0	1
70	Multiple Cranial Nerve Palsies in a Patient with Internal Carotid Artery Dissection. <i>European Neurology</i> , 2007, 58, 125-127.	1.4	8
71	Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 188-195.	8.7	96
72	Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. <i>Journal of Pain</i> , 2007, 8, 737-745.	1.4	132

#	ARTICLE	IF	CITATIONS
73	Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a population-based study. <i>Movement Disorders</i> , 2007, 22, 540-545.	3.9	26
74	Application of the ICHD-II Criteria to the Diagnosis of Primary Chronic Headaches Via a Computerized Structured Record. <i>Headache</i> , 2007, 47, 38-44.	3.9	7
75	Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine. <i>Headache</i> , 2007, 48, 070623002213001-???	3.9	13
76	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007, 188, 146-158.	2.3	41
77	Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. <i>Neuropsychopharmacology</i> , 2007, 32, 1384-1390.	5.4	115

78

#	ARTICLE	IF	CITATIONS
91	l-Arginine/nitric oxide pathway in chronic tension-type headache: relation with serotonin content and secretion and glutamate content. <i>Journal of the Neurological Sciences</i> , 2002, 198, 9-15.	0.6	45
92	Brain-derived neurotrophic factor in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 132, 180-188.	2.3	119
93	Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. <i>Journal of Headache and Pain</i> , 2002, 3, 129-135.	6.0	17
94	Application of the 1988 International Headache Society Diagnostic Criteria in Nine Italian Headache Centers using a Computerized Structured Record. <i>Headache</i> , 2002, 42, 1016-1024.	3.9	13
95	Î²-N-Acetylhexosaminidase in Peripheral Blood Lymphocytes and Monocytes in the Different Forms and Stages of Multiple Sclerosis. <i>Journal of Neurochemistry</i> , 2002, 71, 1168-1176.	3.9	11
96	EXPRESSION OF TNF-Î± mRNA BY PERIPHERAL BLOOD MONONUCLEAR CELLS OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH IFN-Î² 1A. <i>Cytokine</i> , 2001, 14, 294-298.	3.2	8
97	Headache associated with acute ischemic stroke. <i>Journal of Headache and Pain</i> , 2001, 2, 25-29.	6.0	14
98	Event-Related Potentials in Posttraumatic Headache. <i>Headache</i> , 2001, 41, 579-585.	3.9	17
99	Outcome of Juvenile Headache in Outpatients Attending 23 Italian Headache Clinics*. <i>Headache</i> , 1999, 39, 737-746.	3.9	35
100	Radioligand binding assay of M1 and M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. <i>Journal of Neuroimmunology</i> , 1999, 99, 224-229.	2.3	41
101	Activity levels of a Î²1,6 N-acetylglucosaminyltransferase in lymphomonocytes from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1997, 151, 177-183.	0.6	16
102	Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1997, 80, 76-86.	2.3	51
103	Study of Pressure Pain and Cellular Concentration of Neurotransmitters Related to Nociception in Episodic Tension-Type Headache Patients. <i>Headache</i> , 1997, 37, 565-571.	3.9	33
104	Body size and immune responses. <i>Nutrition Research</i> , 1996, 16, 1813-1819.	2.9	9
105	Applicability of the 1988 IHS Criteria to Headache Patients Under the Age of 18 Years Attending 21 Italian Headache Clinics. <i>Headache</i> , 1995, 35, 146-153.	3.9	94
106	Neuropeptide Y in Juvenile Migraine and Tension-Type Headache. <i>Headache</i> , 1994, 34, 35-40.	3.9	28
107	Magnesium Content of Mononuclear Blood Cells in Migraine Patients. <i>Headache</i> , 1994, 34, 160-165.	3.9	36
108	Red Blood Cell Magnesium Levels in Migraine Patients. <i>Cephalalgia</i> , 1993, 13, 94-98.	3.9	35

#	ARTICLE	IF	CITATIONS
109	Nutritional Status and Immune Responses. Clinics in Laboratory Medicine, 1993, 13, 455-461.	1.4	21
110	Serum and Salivary Magnesium Levels in Migraine and Tension-Type Headache. Results in a Group of Adult Patients. Cephalalgia, 1992, 12, 21-27.	3.9	76
111	Serum and Salivary Magnesium Levels in Migraine. Results in a Group of Juvenile Patients. Headache, 1992, 32, 132-135.	3.9	53